Abstract PS8-09: Dietary supplement use in a healthy eating and exercise lifestyle intervention in breast cancer survivors: The lifestyle exercise and nutrition (LEAN) study

Author(s):  
ThaiHien Nguyen ◽  
Maura Harrigan ◽  
Courtney Mcgowan ◽  
Annette Hood ◽  
Fangyong Li ◽  
...  
Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3730
Author(s):  
Maura Harrigan ◽  
Courtney McGowan ◽  
Annette Hood ◽  
Leah M. Ferrucci ◽  
ThaiHien Nguyen ◽  
...  

The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary supplements should not be used for cancer prevention. Several dietary supplements have potential pharmacokinetic and pharmacodynamic interactions that may change their clinical efficacy or potentiate adverse effects of the adjuvant endocrine therapy prescribed for breast cancer treatment. This analysis examined the prevalence of self-reported dietary supplement use and the potential interactions with tamoxifen and aromatase inhibitors (AIs) among breast cancer survivors enrolled in three randomized controlled trials of lifestyle interventions conducted between 2010 and 2017. The potential interactions with tamoxifen and AIs were identified using the Natural Medicine Database. Among 475 breast cancer survivors (2.9 (mean) or 2.5 (standard deviation) years from diagnosis), 393 (83%) reported using dietary supplements. A total of 108 different types of dietary supplements were reported and 36 potential adverse interactions with tamoxifen or AIs were identified. Among the 353 women taking tamoxifen or AIs, 38% were taking dietary supplements with a potential risk of interactions. We observed a high prevalence of dietary supplement use among breast cancer survivors and the potential for adverse interactions between the prescribed endocrine therapy and dietary supplements was common.


2008 ◽  
Vol 26 (4) ◽  
pp. 665-673 ◽  
Author(s):  
Christine M. Velicer ◽  
Cornelia M. Ulrich

Vitamin and mineral supplement use is thought to be common among the 10 million adults in the United States who have been diagnosed with cancer; however, well-conducted studies of this topic are sparse. Moreover, the biologic effects of supplement use among cancer survivors are not well established and not necessarily beneficial. We present a systematic summary of studies published between 1999 and 2006, 32 in total, addressing vitamin and mineral supplement use among US adult cancer patients and survivors. Supplement use is widespread among cancer patients and longer-term survivors. In studies combining different cancer sites, 64% to 81% of survivors reported using any vitamin or mineral supplements and 26% to 77% reported using any multivitamins. In contrast, approximately 50% of US adults use dietary supplements and 33% use multivitamin/multimineral supplements. Between 14% and 32% of survivors initiate supplement use after diagnosis, and use differs by cancer site. Breast cancer survivors reported the highest use, whereas prostate cancer survivors reported the least. Higher level of education and female sex emerged as factors most consistently associated with supplement use. Up to 68% of physicians are unaware of supplement use among their cancer patients. These results highlight the need for further studies of the association between dietary supplement use and cancer treatment toxicity, recurrence, survival, and quality of life to support evidence-based clinical guidelines for dietary supplement use among cancer patients and longer-term survivors.


2019 ◽  
Author(s):  
Mengxi Du ◽  
Jeffrey B. Blumberg ◽  
Zhilei Shan ◽  
Gail Rogers ◽  
Fan Chen ◽  
...  

2021 ◽  
Vol 53 (8S) ◽  
pp. 481-481
Author(s):  
Zachary L. Chaplow ◽  
Marcy L. Haynam ◽  
Victoria R. DeScenza ◽  
Jessica Bowman ◽  
Kathryn Dispennette ◽  
...  

2019 ◽  
Vol 109 (1) ◽  
pp. 69-78 ◽  
Author(s):  
Audrey Y Jung ◽  
Xinting Cai ◽  
Kathrin Thoene ◽  
Nadia Obi ◽  
Stefanie Jaskulski ◽  
...  

ABSTRACT Background There is a paucity of information on the prevalence of dietary supplement use in breast cancer survivors. Only a few studies have examined the impact of dietary supplements, particularly antioxidants, on breast cancer prognosis and the results are inconclusive. Objective We examined pre- and postdiagnosis use of supplements in postmenopausal breast cancer survivors in Germany and investigated associations between postdiagnosis use of antioxidants and other supplements, and prognosis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who received chemotherapy and radiation therapy. Design Data from 2223 postmenopausal women diagnosed with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study were used. Women were interviewed at recruitment in 2002–2005 and again in 2009 and followed-up until 30 June 2015. Multivariate Cox regression analysis was used to estimate HRs and corresponding 95% CIs. Results Pre- and postdiagnosis supplement use was reported by 36% and 45% of the women, respectively. There were 240 deaths (134 from breast cancer) and 200 breast cancer recurrences after a median follow-up time of 6.0 y after the 2009 re-interview. After adjusting for relevant confounders, concurrent antioxidant use with chemotherapy or radiation therapy among 1940 women was associated with increased risk of total mortality (HR: 1.64; 95% CI: 1.01, 2.66) and worsened recurrence-free survival (HR: 1.84; 95% CI: 1.26, 2.68). Overall postdiagnosis supplement use was not associated with breast cancer prognosis. Conclusions Antioxidant use during chemotherapy or radiation therapy was associated with worsened breast cancer prognosis in postmenopausal women. There was no overall association between postdiagnosis supplement use and breast cancer prognosis. Results from our study align with the current recommendation to possibly avoid the use of antioxidants during chemotherapy or radiation therapy.


2020 ◽  
Vol 39 (1) ◽  
pp. 234-241 ◽  
Author(s):  
Janna L. Koole ◽  
Martijn J.L. Bours ◽  
José J.L. Breedveld-Peters ◽  
Eline H. van Roekel ◽  
Stéphanie O. Breukink ◽  
...  

1998 ◽  
Vol 98 (3) ◽  
pp. 285-292 ◽  
Author(s):  
VICKY NEWMAN ◽  
CHERYL L ROCK ◽  
SUSAN FAERBER ◽  
SHIRLEY W FLATT ◽  
FRED A WRIGHT ◽  
...  

2007 ◽  
Vol 21 (5) ◽  
Author(s):  
Paige Elizabeth Miller ◽  
Terryl J Hartman ◽  
Joseph J Vasey ◽  
Pamela F Short

Sign in / Sign up

Export Citation Format

Share Document